Yamo Pharmaceuticals is developing L1-79, the first therapy observed to reduce the core symptoms of autism. L1-79 is a novel, well-tolerated mechanism that targets the central nervous system and metabolic symptoms of autism.
Yamo Pharmaceuticals is developing L1-79, the first therapy observed to reduce the core symptoms of autism as assessed by commonly accepted and validated psychometric tests. L1-79 is a daily oral treatment that is a modified formulation of an agent approved by the U.S. Food and Drug Administration. In preliminary testing, some L1-79 patients, ranging in age from toddler to adult, have exhibited improvement in the core symptoms of autism, including socialization, behavior, irritability, hyperactivity, communication and others. Using standard medical assessments, objective results have been documented in some cases within weeks of starting treatment and have continued over ongoing therapy. Yamo Pharmaceuticals is currently completing a Phase-II clinical trial for use of L1-79 in the treatment of autism.